Trials / Completed
CompletedNCT00419094
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Keppra XR | Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks |
| DRUG | Keppra XR | Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2007-01-08
- Last updated
- 2014-09-05
- Results posted
- 2010-12-20
Locations
45 sites across 4 countries: United States, Mexico, Poland, Russia
Source: ClinicalTrials.gov record NCT00419094. Inclusion in this directory is not an endorsement.